Skip to main content
Erschienen in: Familial Cancer 4/2014

01.12.2014

Muir–Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients

verfasst von: G. Ponti, G. Pellacani, C. Ruini, A. Percesepe, C. Longo, V. Desmond Mandel, F. Crucianelli, G. Gorelli, A. Tomasi

Erschienen in: Familial Cancer | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Primary and secondary immunodepressive conditions are associated with an increased incidence of sebaceous tumors. Microsatellite instability (MSI) and lack of expression of mismatch repair (MMR) proteins, typical markers of Muir–Torre/Lynch heredo-familial settings, can be recognized also in immunocompromised patients. We aimed to carry on a systematic examination of clinical, immunohistochemical, biomolecular features of sebaceous tumors arising in immunocompromised and immunocompetent patients between 1986 and 2012. Microsatellite screening, immunohistochemical analysis and genetic testing were performed for hMLH1, hMSH2 and hMSH6. Methylation status of MMR genes was checked in cases with immunohistochemistry (IHC) loss of MMR proteins expression and no germline mutations. Fifteen patients had a personal history of visceral carcinomas fulfilling diagnostic criteria for Muir–Torre syndrome. In this cohort, IHC analysis, MSI status and genetic testing were in agreement, showing eight MSH2 and two MLH1 germline mutations. Five patients were immunosuppressed and their sebaceous tumors showed a lack of MSH2/MSH6 expression, although just one case with positive family history for visceral cancer harbored a germline mutation. In immunosuppressed patients, loss of IHC for MMR proteins is not necessarily secondary to MMR germline mutations. IHC false positives are probably due to epigenetic alterations. MSI and lack of expression of MMR proteins can be recognized also in immunocompromised patients without MMR germline mutations.
Literatur
1.
Zurück zum Zitat London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP (1995) Risk of neoplasia in renal transplant patients. Lancet 346:403–406PubMedCrossRef London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP (1995) Risk of neoplasia in renal transplant patients. Lancet 346:403–406PubMedCrossRef
2.
Zurück zum Zitat Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O et al (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177–186PubMedCrossRef Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O et al (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177–186PubMedCrossRef
3.
Zurück zum Zitat Glover MT, Niranjan N, Kwan JT, Leigh IM (1994) Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 47:86–89PubMedCrossRef Glover MT, Niranjan N, Kwan JT, Leigh IM (1994) Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 47:86–89PubMedCrossRef
4.
Zurück zum Zitat Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R et al (2003) High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 48:401–408PubMedCrossRef Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R et al (2003) High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 48:401–408PubMedCrossRef
6.
Zurück zum Zitat Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E et al (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26:158–163PubMedCrossRef Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E et al (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26:158–163PubMedCrossRef
7.
Zurück zum Zitat Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV et al (2001) An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 116:246–253PubMedCrossRef Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV et al (2001) An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 116:246–253PubMedCrossRef
8.
Zurück zum Zitat Capello D, Rossi D, Gaidano G (2005) Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 23:61–67PubMedCrossRef Capello D, Rossi D, Gaidano G (2005) Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 23:61–67PubMedCrossRef
9.
Zurück zum Zitat Carbone A (2003) Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 4:22–29PubMedCrossRef Carbone A (2003) Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 4:22–29PubMedCrossRef
10.
Zurück zum Zitat Gaidano G, Pasqualucci L, Capello D, Berra E, Deambrogi C, Rossi D et al (2003) Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102:1833–1841PubMedCrossRef Gaidano G, Pasqualucci L, Capello D, Berra E, Deambrogi C, Rossi D et al (2003) Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102:1833–1841PubMedCrossRef
11.
Zurück zum Zitat Landis MN, Davis CL, Bellus GA, Wolverton SE (2011) Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir–Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 65:1054–1058PubMedCrossRef Landis MN, Davis CL, Bellus GA, Wolverton SE (2011) Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir–Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 65:1054–1058PubMedCrossRef
12.
Zurück zum Zitat Pedroni M, Sala E, Scarselli A, Borghi F, Menigatti M, Benatti P et al (2001) Microsatellite instability and mismatch-repair protein expression in hereditary and sporadic colorectal carcinogenesis. Cancer Res 61:896–899PubMed Pedroni M, Sala E, Scarselli A, Borghi F, Menigatti M, Benatti P et al (2001) Microsatellite instability and mismatch-repair protein expression in hereditary and sporadic colorectal carcinogenesis. Cancer Res 61:896–899PubMed
13.
Zurück zum Zitat Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356(7):697–705PubMedCrossRef Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356(7):697–705PubMedCrossRef
14.
Zurück zum Zitat Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117PubMedCrossRef Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117PubMedCrossRef
15.
Zurück zum Zitat Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM et al (1996) Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56:4836–4840PubMed Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM et al (1996) Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56:4836–4840PubMed
16.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef
18.
Zurück zum Zitat Ponti G, Losi L, Di Gregorio C, Roncucci L, Pedroni M, Scarselli A et al (2005) Identification of Muir–Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 103:1018–1025PubMedCrossRef Ponti G, Losi L, Di Gregorio C, Roncucci L, Pedroni M, Scarselli A et al (2005) Identification of Muir–Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 103:1018–1025PubMedCrossRef
19.
Zurück zum Zitat Chhibber V, Dresser K, Mahalingam M (2008) MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir–Torre syndrome. Mod Pathol 2:159–164 Chhibber V, Dresser K, Mahalingam M (2008) MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir–Torre syndrome. Mod Pathol 2:159–164
20.
Zurück zum Zitat Mathiak M, Rütten A, Mangold E, Fischer HP, Ruzicka T, Friedl W et al (2002) Loss of DNA mismatch repair proteins in skin tumors from patients with Muir–Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 26:338–343PubMedCrossRef Mathiak M, Rütten A, Mangold E, Fischer HP, Ruzicka T, Friedl W et al (2002) Loss of DNA mismatch repair proteins in skin tumors from patients with Muir–Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 26:338–343PubMedCrossRef
21.
Zurück zum Zitat Morales-Burgos A, Sánchez JL, Figueroa LD, De Jesús-Monge WE, Cruz-Correa MR, González-Keelan C et al (2008) MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J 27:322–327 Morales-Burgos A, Sánchez JL, Figueroa LD, De Jesús-Monge WE, Cruz-Correa MR, González-Keelan C et al (2008) MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J 27:322–327
22.
Zurück zum Zitat Kruse R, Rütten A, Schweiger N, Jakob E, Mathiak M, Propping P et al (2003) Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 120:858–864PubMedCrossRef Kruse R, Rütten A, Schweiger N, Jakob E, Mathiak M, Propping P et al (2003) Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 120:858–864PubMedCrossRef
24.
Zurück zum Zitat Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Mallorca group et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823PubMedCentralPubMedCrossRef Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Mallorca group et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823PubMedCentralPubMedCrossRef
25.
26.
Zurück zum Zitat Roberts ME, Riegert-Johnson DL, Thomas BC et al (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir–Torre variant of Lynch syndrome. Genet Med 6. doi:10.1038/gim.2014.19 Roberts ME, Riegert-Johnson DL, Thomas BC et al (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir–Torre variant of Lynch syndrome. Genet Med 6. doi:10.​1038/​gim.​2014.​19
27.
Zurück zum Zitat Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G et al (2006) Value of MLH1 and MSH2 mutations in the appearance of Muir–Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 126:2302–2307PubMedCrossRef Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G et al (2006) Value of MLH1 and MSH2 mutations in the appearance of Muir–Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 126:2302–2307PubMedCrossRef
28.
Zurück zum Zitat Hitchins MP, Owens SE, Kwok CT, Godsmark G, Algar UF, Ramesar RS (2011) Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse South African cohort. Clin Genet 80:428–434PubMedCrossRef Hitchins MP, Owens SE, Kwok CT, Godsmark G, Algar UF, Ramesar RS (2011) Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse South African cohort. Clin Genet 80:428–434PubMedCrossRef
29.
Zurück zum Zitat Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong JJ, Khachigian LM et al (2011) Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5′UTR. Cancer Cell 20:200–213PubMedCrossRef Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong JJ, Khachigian LM et al (2011) Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5′UTR. Cancer Cell 20:200–213PubMedCrossRef
30.
Zurück zum Zitat Griffard EA, McCoppin HH, Wieberg J, Feldman M (2011) The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir–Torre syndrome. J Am Acad Dermatol 64:86–87CrossRef Griffard EA, McCoppin HH, Wieberg J, Feldman M (2011) The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir–Torre syndrome. J Am Acad Dermatol 64:86–87CrossRef
31.
Zurück zum Zitat Andrés A (2005) Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56:71–85PubMedCrossRef Andrés A (2005) Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56:71–85PubMedCrossRef
32.
Zurück zum Zitat Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC (1997) The Muir–Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol 24:511–518PubMedCrossRef Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC (1997) The Muir–Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol 24:511–518PubMedCrossRef
Metadaten
Titel
Muir–Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients
verfasst von
G. Ponti
G. Pellacani
C. Ruini
A. Percesepe
C. Longo
V. Desmond Mandel
F. Crucianelli
G. Gorelli
A. Tomasi
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9733-4

Weitere Artikel der Ausgabe 4/2014

Familial Cancer 4/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.